Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Chronic Hepatitis C, Genotype 1
HCV RNA \>100,000 IU/mL at screening;
Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg);
Liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and will be capped at approximately 10%

Any evidence of liver disease other than HCV;
Co-infection with HIV;
Diagnosed or suspected hepatocellular carcinoma;
Medical history or laboratory value abnormalities that would prohibit the use of Pegylated Interferon Alpha-2a or Ribavirin

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin